File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma

TitleA pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma
Authors
Issue Date2003
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2003, v. 97 n. 11, p. 2776-2782 How to Cite?
AbstractBACKGROUND. Systemic, high-dose interferon-α treatment given three times per week subcutaneously induces tumor regression in approximately 30% of patients with inoperable hepatocellular carcinoma (HCC). The objective of the current study was to determine the efficacy and safety of transcatheter arterial interferon embolization for the treatment of patients with inoperable HCC. METHODS. Eighteen patients with inoperable HCC were recruited to receive 3 different doses of interferon-a-2b (10 megaunits [MU]/m2, 30 MU/m2, or 50 MU/m2) at intervals of 8-12 weeks. Their tumor response, adverse events, and survival were monitored. RESULTS. In 14 patients with nondiffuse HCC, complete responses and partial responses (> 50% tumor reduction) were observed in 28.6% and 35.7% of patients, respectively. One of four patients with diffuse HCC had a partial response. Thirty-eight percent of patients had normalization of their α-fetoprotein level. The median ferritin level at the last follow-up was reduced significantly (765 pmol/L; range, 457-2720 pmol/L) compared with the baseline level (1980 pmol/L; range, 1100-3300 pmol/L; P = 0.011). The median survival was 15.9 months. Transient fever and rigor were the most common side effects observed. Five patients (27.8%) developed hypothyroidism. No significant liver decompensation was observed. CONCLUSIONS. This pilot study showed that transcatheter arterial interferon embolization was an effective method for the treatment of patients with inoperable HCC without significant hepatic toxicity. © 2003 American Cancer Society.
Persistent Identifierhttp://hdl.handle.net/10722/162701
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_US
dc.contributor.authorOoi, CGCen_US
dc.contributor.authorHui, CKen_US
dc.contributor.authorWong, WMen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorChan, AOOen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:22:30Z-
dc.date.available2012-09-05T05:22:30Z-
dc.date.issued2003en_US
dc.identifier.citationCancer, 2003, v. 97 n. 11, p. 2776-2782en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162701-
dc.description.abstractBACKGROUND. Systemic, high-dose interferon-α treatment given three times per week subcutaneously induces tumor regression in approximately 30% of patients with inoperable hepatocellular carcinoma (HCC). The objective of the current study was to determine the efficacy and safety of transcatheter arterial interferon embolization for the treatment of patients with inoperable HCC. METHODS. Eighteen patients with inoperable HCC were recruited to receive 3 different doses of interferon-a-2b (10 megaunits [MU]/m2, 30 MU/m2, or 50 MU/m2) at intervals of 8-12 weeks. Their tumor response, adverse events, and survival were monitored. RESULTS. In 14 patients with nondiffuse HCC, complete responses and partial responses (> 50% tumor reduction) were observed in 28.6% and 35.7% of patients, respectively. One of four patients with diffuse HCC had a partial response. Thirty-eight percent of patients had normalization of their α-fetoprotein level. The median ferritin level at the last follow-up was reduced significantly (765 pmol/L; range, 457-2720 pmol/L) compared with the baseline level (1980 pmol/L; range, 1100-3300 pmol/L; P = 0.011). The median survival was 15.9 months. Transient fever and rigor were the most common side effects observed. Five patients (27.8%) developed hypothyroidism. No significant liver decompensation was observed. CONCLUSIONS. This pilot study showed that transcatheter arterial interferon embolization was an effective method for the treatment of patients with inoperable HCC without significant hepatic toxicity. © 2003 American Cancer Society.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_US
dc.relation.ispartofCanceren_US
dc.rightsCancer. Copyright © John Wiley & Sons, Inc.-
dc.subject.meshAgeden_US
dc.subject.meshCarcinoma, Hepatocellular - Mortality - Therapyen_US
dc.subject.meshChemoembolization, Therapeutic - Adverse Effects - Methodsen_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-Alpha - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshLiver Neoplasms - Mortality - Therapyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPilot Projectsen_US
dc.subject.meshRecombinant Proteinsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleA pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1002/cncr.11400en_US
dc.identifier.pmid12767090-
dc.identifier.scopuseid_2-s2.0-0038521455en_US
dc.identifier.hkuros80552-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0038521455&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume97en_US
dc.identifier.issue11en_US
dc.identifier.spage2776en_US
dc.identifier.epage2782en_US
dc.identifier.isiWOS:000183022100010-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridOoi, CGC=7007084909en_US
dc.identifier.scopusauthoridHui, CK=7202876933en_US
dc.identifier.scopusauthoridWong, WM=7403972413en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridChan, AOO=7403167965en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats